NASDAQ: BRKR

Bruker (BRKR) Stock Analysis & Forecast

Nov 13 close

$61.59+1.26 (+2.1%)

Gekko Brief

Nov 9 close

Bruker closed at $66.54 on 9 November 2026, +8.5% on the day. The price sits above both the 50-day ($59.20) and 200-day ($50.52) moving averages, inside a 52-week range of $32.37 to $68.98. The GekkoIndex reads 50.8, in the Neutral zone, down 10.6 points over five sessions. Gekko Fair Value is $51.10, so the price is 30.2% above it.

The next earnings report is due on 11 February 2027, 88 days away (before open). Over the last 8 reports the company beat the earnings estimate 6 times, with an average move of 9.4% across the report. Over the last 30 days there was 1 unusual options signal. Seasonally, the next 20 trading days from this point averaged +5.7% over the last 5 years, rising in 3 of them.

8 firms rate the stock: 3 buy, 4 hold and 1 sell, with a consensus target of $63.83. A typical daily move is about 6.4%, and a typical 20-day move about 7%. On the swing-trade checklist, 3 items read supportive and 2 read as a headwind (fair value, smart money).

A plain summary of the figures as of the Nov 9, 2026 close.

Bruker price vs fair value

$61.59$51.79Nov ’25May ’26Nov ’26
Close $61.59200-day averageGekko Fair Value $51.79

Bruker quick facts

Market cap
$9.41B
P/E ratio
—
Forward P/E
13.8
EPS, TTM
−$1.10
Revenue, TTM
$3.51B
Profit margin
-3.5%
Dividend yield
0.08%
Beta
1.27
Volume
2.02M avg 2.61M
1-year return
+45.0%
Typical daily move
±7%
Typical 20-day move
±7%
50-day average
$59.48
200-day average
$50.82
Next earnings
Feb 11 before open
Shares outstanding
152.7M
52-week range
$32.37$68.98

Bruker swing-trade checklist

Bruker scores 3 supportive, 1 mixed and 2 headwinds across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive1 mixed2 headwinds

  • Trendsupportive

    Above 50 and 200-day

    Close $61.59 is above the 50-day ($59.48) and 200-day ($50.82) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    57.6, Neutral

    Reading 57.6 is in the Neutral zone.

    See the GekkoIndex
  • Fair valueheadwind

    18.9% above

    Price is 18.9% above Gekko Fair Value (more than 5% above).

    See fair value
  • Smart moneyheadwind

    Leans bearish

    Last 30 days: 1 unusual options signal.

    See smart money
  • Earnings risksupportive

    Reports in 88 days

    Next report Feb 11, 2027, 88 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +5.1% on average

    From this point in the calendar, the next 20 trading days averaged +5.1% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Bruker stock chart and price history

Bruker closed at $61.59 on Nov 13, 2026, +45.0% over the past year, inside a 52-week range of $32.37 to $68.98.

Close50-day average200-day averageVolume
Bruker share price, past year, with 50-day and 200-day moving averages and volume$40$50DecJan 2026FebMarAprMayJunJulAugSepOctNov61.59

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+8.9%
3 months
+6.8%
6 months
+43.6%
1 year
+45.0%
The full BRKR chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open BRKR in Gekko

Follow Bruker through every session

Put BRKR on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track BRKR in GekkoFree for 7 days. No credit card required.

About Bruker

Bruker designs, builds and sells scientific instruments used for research, analysis and diagnostics. Its offerings span mass spectrometry systems, X-ray equipment, atomic force microscopy tools and optical fluorescence microscopy, along with diagnostic products such as the MALDI Biotyper for pathogen identification, molecular test kits, DNA test strips and PCR-based testing, including solutions developed for SARS-CoV-2 detection.

The business is organized into three segments: Life Science, NANO, and Energy & Supercon Technologies. Life Science covers instruments and diagnostics for research and clinical use, along with products supporting multi-omics work in drug and biomarker discovery. NANO focuses on tools such as X-ray metrology, AFM defect detection, and equipment for photomask repair and cleaning. The Energy segment supplies superconducting materials, including metallic low-temperature superconductors, and related equipment such as synchrotron and beamline instrumentation. Bruker also works with Newomics Inc. on an LC-MS platform aimed at drug discovery.

Bruker was founded in 1991 and is headquartered in Billerica, Massachusetts. Its shares are listed on the NASDAQ under the ticker BRKR.

Listed
NASDAQ
Sector
Health technology
Industry
Medical specialties
Website
bruker.com

Bruker GekkoIndex: the smart money zone

Bruker’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 57.6, in the Neutral zone, up 2.9 points over five sessions.

010057.6Neutral

Up 2.9 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying50+3.2%+2.0%+0.4%+5.8%
Accumulation260−0.2%−0.9%−1.9%+1.2%
Neutral (current zone)355−0.2%+0.5%+1.3%−0.6%
Distribution31+1.2%+1.7%+3.5%−10.1%
Selling6Too few readings yet

Average BRKR share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the BRKR price, zone by zone.Track BRKR in Gekko

Is Bruker stock overvalued? Gekko Fair Value

Bruker trades 18.9% above Gekko Fair Value of $51.79, so the shares are overvalued on Gekko’s estimate.

Gekko’s own estimate of what Bruker shares are worth, recalculated every trading day.

$51.79

Gekko Fair Value, Nov 14, 2026

18.9% Overvalued

At the end of Aug 2026 the price was 17.2% above the estimate.

Gekko Fair ValueShare price, month end
$52$62Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open BRKR in Gekko

Bruker insider and Congress trading

No open-market insider purchases were filed for Bruker, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for BRKR in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every BRKR insider filing, plotted on the chart in Gekko.Open BRKR in Gekko

Congress trades last 90 days

No trades in BRKR were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for BRKR, plotted on the chart in Gekko.Open BRKR in Gekko

Buybacks

Bruker has been buying back its own shares.

Bought back, quarter ended Mar 31, 2025
$10.00M
As a share of market cap
0.11%

From company filings.

Unusual options activity last 30 days

1signal, 22% of the flagged premium in calls.

Latest: Bearish flow on Nov 4, $763K in unusual premium.

Hedge funds and billionaires quarter ended Jun 30

2of the funds Gekko tracks hold BRKR.

0added2opened0trimmed0sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko

Bruker earnings: next date and track record

Bruker reports on Feb 11, 2027, before the open (88 days away), and beat the EPS estimate in 6 of its last 8 reports.

6 of 8reports beat the EPS estimate
±9.4%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

−3.1%Feb ’25+2.7%May ’25−15.6%Aug ’25+3.7%Nov ’25−14.0%Feb ’26+15.0%May ’26−18.4%Aug ’26+2.8%Nov ’26

Last earnings call, Nov 4, 2026 AI summary

What they said
Bruker reported Q3 2026 results featuring five consecutive quarters of BSI book-to-bill above 1.0. Key highlights include double-digit U.S. academic/government bookings growth (first YoY increase since 2025 NIH disruption), 20%+ organic bookings growth in China, and 30%+ growth in semiconductor metrology markets driven by AI demand. The company made a minority investment in Atinary Technologies to integrate AI-driven workflows with Bruker instruments.
Guidance
Management expects continued U.S. academic/government bookings growth in Q4. Semiconductor metrology orders are expected to convert to revenue mostly in fiscal 2027 and some in 2028. Full year 2026 outlook to be detailed by CFO Gerald Herman.
ReportedEPSSurpriseRevenueSurpriseMove
Nov 4, 2026$0.56
est $0.42
+33.6%$874.0M
est $865.2M
+1.0%+2.8%
Aug 4, 2026$0.49
est $0.38
+27.3%$838.5M
est $853.6M
−1.8%−18.4%
May 6, 2026$0.31
est $0.23
+34.8%$823.4M
est $795.6M
+3.5%+15.0%
Feb 12, 2026$0.59
est $0.65
−9.2%$977.2M
est $962.3M
+1.6%−14.0%
Nov 3, 2025$0.45
est $0.32
+40.6%$860.5M
est $964.6M
−10.8%+3.7%
Aug 4, 2025$0.32
est $0.33
−3.0%$797.4M
est $810.2M
−1.6%−15.6%
May 7, 2025$0.47
est $0.46
+2.2%$801.4M
est $819.9M
−2.3%+2.7%
Feb 13, 2025$0.76
est $0.74
+2.7%$979.6M
est $965.6M
+1.4%−3.1%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Bruker stock forecast and analyst price targets

Analysts’ average 12-month price target for Bruker is $68.00, +10.4% from the last close, from 8 firms rating the stock in the last 90 days.

$68.00consensus 12-month target, +10.4% from the last close
Low $55High $85
Buy3
Hold4
Sell1

Each firm’s latest rating in the last 90 days: 8 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 10GuggenheimBuy, reiterated$72+16.9%
Nov 5Leerink PartnersBuy, maintained$85+38.0%
Nov 5J.P. MorganHold, maintained$60−2.6%
Nov 5CitiHold, maintained$64+3.9%
Nov 5BarclaysBuy, maintained$70+13.7%
+1.3%average 20-day move after past Neutral readings
+5.1%average move over the next 20 trading days in the last 5 years
±7%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Bruker seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Bruker averaged +5.1% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

−3.0%2021−3.4%2022+17.5%2023+5.9%2024+9.7%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days+1.5%2 of 5
Next 10 trading days+3.4%3 of 5
Next 15 trading days+3.9%3 of 5
Next 20 trading days+5.1%3 of 5
Next 30 trading days+7.1%4 of 5

For scale, BRKR’s typical 20-trading-day move in either direction is about 7%.

Bruker market cap and key statistics

Bruker’s market cap is $9.41B and revenue of $3.51B over the last twelve months.

Valuation

Market cap
$9.41B
Forward P/E
13.8
EPS, TTM
−$1.10
Gekko Fair Value
$51.79

Trading

Volume
2.02M
Avg volume, 20 days
2.61M
52-week high
$68.98
52-week low
$32.37
Shares outstanding
152.7M

Financials

Revenue, TTM
$3.51B
Profit margin
-3.5%
Return on equity
-4.8%
Quarterly earnings growth, YoY
−81.8%

Risk and income

Beta
1.27
Typical daily move
±7%
Typical 20-day move
±7%
Dividend yield
0.08%

Bruker stock news this week

Coverage of Bruker this week reads positive: 3 positive, 1 neutral and 0 negative headlines.

News sentiment positive

Bruker peers

Bruker’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
TMOThermo Fisher Scientific−0.2%Neutral15.0% above
ABTAbbott Laboratories+0.3%Neutral10.5% below
DHRDanaher0.0%Neutral4.7% above
ISRGIntuitive Surgical0.0%Neutral17.5% above
MDTMedtronic+0.7%Neutral14.2% below
SYKStryker−2.0%Neutral0.1% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Medical specialties

Bruker stock FAQ

What is Bruker’s market cap?

Bruker’s market cap is $9.41B at the Nov 13, 2026 close of $61.59, with 152.7M shares outstanding.

What is the Bruker stock forecast?

The consensus analyst 12-month price target for Bruker is $68.00, +10.4% from the last close. Of the 8 firms that rated the stock in the last 90 days, 3 rate it a buy, 4 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.

Is Bruker stock overvalued or undervalued?

On Gekko’s estimate Bruker is overvalued: the Nov 13, 2026 close of $61.59 is 18.9% above Gekko Fair Value of $51.79. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Bruker report earnings next?

Bruker is expected to report on Feb 11, 2027, before the market opens (88 days away). Analysts expect earnings of $0.77 per share on revenue of $1.00B. Bruker beat the earnings estimate in 6 of its last 8 reports, moving 9.4% on average across the report.

What is Bruker’s 52-week high and low?

Bruker’s 52-week high is $68.98 and its 52-week low is $32.37; it closed at $61.59 on Nov 13, 2026, +45.0% over the past year. Over the last five years the shares peaked at $94.86 on Mar 21, 2024.

Is Bruker stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (trend, earnings risk and seasonality), 1 as mixed (gekkoindex) and 2 as headwinds (fair value and smart money). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in Bruker?

Gekko flagged 1 unusual options signal in Bruker over the last 30 days, with $164K of flagged premium in calls and $599K in puts. The latest, bearish flow, was on Nov 4, 2026 with $763K in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Bruker the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.